Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment
Time to recurrence · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyHR 0.02 [0, 0.22]1 study · 21 participantsVery low